XML 61 R36.htm IDEA: XBRL DOCUMENT v3.25.3
Stock-Based Compensation (Tables)
 12 Months Ended
Sep. 30, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Awards Outstanding
The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:
As of September 30, 2025
2013 Plan2021 PlanInducement AwardsTotal
Granted and outstanding awards:
Options776,279 32,151 598,605 1,407,035 
Restricted stock units1,500,000 3,750,071 560,280 5,810,351 
Total2,276,279 3,782,222 1,158,885 7,217,386 
Schedule of Share-Based Payment Arrangement, Expensed
The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:
Year Ended September 30,
202520242023
(in thousands)
Research and development$27,320 $29,527 $34,332 
General and administrative27,528 37,570 43,798 
Total $54,848 $67,097 $78,130 
Schedule of Summarized Information about Stock Options
The following table presents a summary of the stock option activity for the year ended September 30, 2025:
SharesWeighted-
Average
Exercise
Price
Per Share		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value
Outstanding at September 30, 20241,978,516 $23.39 
Granted— — 
Cancelled or expired(36,341)45.44 
Exercised(535,140)7.41 
Outstanding at September 30, 20251,407,035 $28.90 3.4$19,099,141 
Exercisable at September 30, 20251,407,035 $28.90 3.4$19,099,141 
Schedule of Assumptions Used to Value Stock Options
The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model:
Year Ended September 30,
2025(5)
2024(5)
2023
Expected dividend yield(1)
— — — 
Risk-free interest rate(2)
N/AN/A
3.69% – 4.57%
Expected volatility(3)
N/AN/A86.4 %
Expected term (in years)(4)
N/AN/A6.25
Weighted-average grant date fair value per shareN/AN/A25.61
(1) The dividend yield is zero as the Company currently does not pay a dividend.
(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.
(3) Volatility is estimated based on volatility average of the Company’s common stock price.
(4) The computation of expected term was determined based on safe harbor rules, considering the contractual terms of the awards and vesting schedules.
(5) No options were granted during the year ended September 30, 2025 and September 30, 2024.
Schedule of Share Activity Related to RSUs
The following table summarizes the activity of the Company’s RSUs:
Number of
RSUs		Weighted-
Average
Grant
Date
Fair Value
Outstanding as of September 30, 20244,913,312 $49.61 
Granted2,779,689 19.38 
Vested(1,525,693)47.15 
Forfeited(356,957)30.19 
Outstanding as of September 30, 20255,810,351 $36.97